Next Financial Group’s Alaunos Therapeutics TCRT Stock Holding History

Next Financial Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7	Closed	-$4K	–	2707
2021 Q1	$4K	Buy	+7	New	+$4.36K	﹤0.01%	2181

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Next Financial Group's TCRT Position: Q2 2021 in Review

Next Financial Group sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 7 shares — an estimated $4K sold.

Next Financial Group first reported a position in TCRT in Q1 2021 and held it in 1 quarter. The position peaked at $4K in Q1 2021. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

Next Financial Group reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
Next Financial Group sold 7 Alaunos Therapeutics shares in Q2 2021, an estimated $4K.
Next Financial Group first reported a position in Alaunos Therapeutics in Q1 2021 and held it in 1 quarter.
Next Financial Group's Alaunos Therapeutics position peaked at $4K in Q1 2021.
155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on Next Financial Group's 13F filing for Q2 2021, filed 13 Jul 2021.